Skip to content

Study · Animal study (in vivo) · rat · 1985

2 results

Behaviorally active oxytocin fragments simultaneously attenuate heroin self-administration and tolerance in rats.

Kovács CL, Van Ree JM

Life sciences1 Nov 1985Cited by 34 (Europe PMC)

PMID4058258 (opens in a new tab)DOI10.1016/0024-3205(85)90007-4 (opens in a new tab)PepBankPUB-04058258
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In heroin-tolerant rats, subcutaneous oxytocin decreased the amount of heroin self-injected.

    In plain wordsIn rats tolerant to heroin, oxytocin reduced the amount of heroin they self-injected.

    Peptide
    Oxytocin
    Outcome
    DecreaseAmount of heroin self-injected
    Study

    Ratn: not reported in source

    Heroin-tolerant rats self-administering heroin
    Outcome group
    Addiction, withdrawal and alcohol intake · Nervous system and cognition
    Studied dose
    Dose not stated · SubcutaneousAs given in this study (Rat).

    Source sentences

    Summary
    Subcutaneous injection of oxytocin (OXT-(1-9)) and of its behaviorally active fragments desglycinamide9-oxytocin (OXT-(1-8)) and [pGlu4,Cyt6]-oxytocin-(4-8) (OXT-(4-8)) decreased the amount of heroin self-injected.
    1 context sentence
    Summary · context
    Maintenance of intravenous heroin self-administration and the degree of tolerance to the analgesic effect of self-injected heroin were simultaneously measured in heroin-tolerant rats.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In heroin-tolerant rats, PLG was ineffective at reducing the amount of heroin self-injected.

    In plain wordsIn rats tolerant to heroin, MIF‑1 did not reduce the amount of heroin they self-injected.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    No significant changeAmount of heroin self-injected
    Study

    Ratn: not reported in source

    Heroin-tolerant rats self-administering heroin
    Outcome group
    Addiction, withdrawal and alcohol intake · Nervous system and cognition
    Studied dose
    Dose not stated · SubcutaneousAs given in this study (Rat).

    Source sentences

    Summary
    The C-terminal tripeptide of oxytocin (prolyl-leucyl-glycinamide, PLG, OXT-(7-9)) and desglycinamide9-[Arg]8-vasopressin (AVP-(1-8] were ineffective in this respect.
    2 context sentences
    Summary · context
    Subcutaneous injection of oxytocin (OXT-(1-9)) and of its behaviorally active fragments desglycinamide9-oxytocin (OXT-(1-8)) and [pGlu4,Cyt6]-oxytocin-(4-8) (OXT-(4-8)) decreased the amount of heroin self-injected.
    Summary · context
    Maintenance of intravenous heroin self-administration and the degree of tolerance to the analgesic effect of self-injected heroin were simultaneously measured in heroin-tolerant rats.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:52 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.